SEC Form 4 · accession 0001104659-26-070521
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Leslie E Donato
Director
Period of report
Jun 2, 2026
Accepted (ET)
Jun 4, 2026 · 4:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 2, 2026 | M | 4,882 | — | A | 4,882 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jun 2, 2026 | M | 4,882 | D | — | — | Ordinary Shares | 4,882 | 3,984 | D |
Explanation of responses
- F1Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
- F2The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.